share_log

Panbela Therapeutics | S-1: General form for registration of securities under the Securities Act of 1933

Panbela Therapeutics | S-1: General form for registration of securities under the Securities Act of 1933

Panbela Therapeutics | S-1：证券上市注册声明
美股sec公告 ·  03/29 17:28
Moomoo AI 已提取核心信息
Panbela Therapeutics, Inc. (Panbela), a clinical-stage biopharmaceutical company, has filed a registration statement with the Securities and Exchange Commission (SEC) on March 29, 2024, for the potential resale of up to 255,600 shares of common stock by certain selling securityholders. These shares are issuable upon the exercise of Class D common stock purchase warrants, known as Inducement Warrants, which were issued following the exercise of existing Class C warrants by the selling securityholders. The Inducement Warrants, with an initial exercise price of $19.00 per share, will only become exercisable upon obtaining stockholder approval as required by Nasdaq listing rules. Panbela will not receive any proceeds from the sale of shares by the selling securityholders but will bear all costs associated with the registration. The registration is part of Panbela's commitment to enable the selling securityholders to sell their shares, which may include shares acquired through warrant exercises. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'PBLA'.
Panbela Therapeutics, Inc. (Panbela), a clinical-stage biopharmaceutical company, has filed a registration statement with the Securities and Exchange Commission (SEC) on March 29, 2024, for the potential resale of up to 255,600 shares of common stock by certain selling securityholders. These shares are issuable upon the exercise of Class D common stock purchase warrants, known as Inducement Warrants, which were issued following the exercise of existing Class C warrants by the selling securityholders. The Inducement Warrants, with an initial exercise price of $19.00 per share, will only become exercisable upon obtaining stockholder approval as required by Nasdaq listing rules. Panbela will not receive any proceeds from the sale of shares by the selling securityholders but will bear all costs associated with the registration. The registration is part of Panbela's commitment to enable the selling securityholders to sell their shares, which may include shares acquired through warrant exercises. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'PBLA'.
处于临床阶段的生物制药公司Panbela Therapeutics, Inc.（Panbela）已于2024年3月29日向美国证券交易委员会（SEC）提交了注册声明，某些出售证券持有人可能转售多达255,600股普通股。这些股票可在行使D类普通股购买权证（即激励认股权证）后发行，该认股权证是在出售证券持有人行使现有的C类认股权证之后发行的。激励认股权证的初始行使价为每股19.00美元，只有在根据纳斯达克上市规则的要求获得股东批准后才能行使。Panbela不会从出售证券持有人出售股票中获得任何收益，但将承担与注册有关的所有费用。此次注册是Panbela承诺的一部分，即允许出售的证券持有人出售其股票，其中可能包括通过认股权证行使获得的股份。该公司的普通股在纳斯达克资本市场上市，股票代码为 “PBLA”。
处于临床阶段的生物制药公司Panbela Therapeutics, Inc.（Panbela）已于2024年3月29日向美国证券交易委员会（SEC）提交了注册声明，某些出售证券持有人可能转售多达255,600股普通股。这些股票可在行使D类普通股购买权证（即激励认股权证）后发行，该认股权证是在出售证券持有人行使现有的C类认股权证之后发行的。激励认股权证的初始行使价为每股19.00美元，只有在根据纳斯达克上市规则的要求获得股东批准后才能行使。Panbela不会从出售证券持有人出售股票中获得任何收益，但将承担与注册有关的所有费用。此次注册是Panbela承诺的一部分，即允许出售的证券持有人出售其股票，其中可能包括通过认股权证行使获得的股份。该公司的普通股在纳斯达克资本市场上市，股票代码为 “PBLA”。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息